Public Health

Landmark verdict

Print edition : May 03, 2013

Buying Glivec at a pharmacy in a government-run hospital in Ahmedabad on April 2. Photo: AMIT DAVE/REUTERS

Anand Grover, a lawyer for the Cancer Patients Aid Association, who led the legal fight against Novartis, showing a package of the generic drug made by an Indian company, at a press conference in New Delhi on April 1. A month's supply of this drug costs $175 whereas an equivalent quantity of Novartis' drug would cost $2,600. Photo: Manish Swarup/AP

The Supreme Court’s ruling against Novartis’ patent claim for the cancer drug Glivec paves the way for generic drug companies to keep crucial, life-saving drugs affordable to the common people.
    This article is closed for comments.
    Please Email the Editor
    ×